X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PFIZER - Comparison Results

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PFIZER VENUS REMEDIES/
PFIZER
 
P/E (TTM) x -9.4 34.5 - View Chart
P/BV x 0.1 5.1 2.9% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 VENUS REMEDIES   PFIZER
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
PFIZER
Mar-18
VENUS REMEDIES/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1432,365 6.0%   
Low Rs651,625 4.0%   
Sales per share (Unadj.) Rs324.2430.3 75.3%  
Earnings per share (Unadj.) Rs6.478.7 8.1%  
Cash flow per share (Unadj.) Rs40.693.2 43.5%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs366.0586.5 62.4%  
Shares outstanding (eoy) m12.3445.75 27.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.6 6.9%   
Avg P/E ratio x16.225.3 63.9%  
P/CF ratio (eoy) x2.621.4 12.0%  
Price / Book Value ratio x0.33.4 8.3%  
Dividend payout %025.4 0.0%   
Avg Mkt Cap Rs m1,28291,271 1.4%   
No. of employees `0000.92.6 34.3%   
Total wages/salary Rs m2513,143 8.0%   
Avg. sales/employee Rs Th4,430.17,484.8 59.2%   
Avg. wages/employee Rs Th278.01,195.0 23.3%   
Avg. net profit/employee Rs Th87.61,369.1 6.4%   
INCOME DATA
Net Sales Rs m4,00019,685 20.3%  
Other income Rs m231,143 2.0%   
Total revenues Rs m4,02320,828 19.3%   
Gross profit Rs m7855,003 15.7%  
Depreciation Rs m422663 63.6%   
Interest Rs m3444 8,183.3%   
Profit before tax Rs m425,479 0.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-371,878 -2.0%   
Profit after tax Rs m793,601 2.2%  
Gross profit margin %19.625.4 77.2%  
Effective tax rate %-87.934.3 -256.4%   
Net profit margin %2.018.3 10.8%  
BALANCE SHEET DATA
Current assets Rs m2,60624,167 10.8%   
Current liabilities Rs m1,9809,544 20.7%   
Net working cap to sales %15.674.3 21.1%  
Current ratio x1.32.5 52.0%  
Inventory Days Days12855 232.9%  
Debtors Days Days4329 150.3%  
Net fixed assets Rs m5,3539,514 56.3%   
Share capital Rs m123458 27.0%   
"Free" reserves Rs m4,39326,375 16.7%   
Net worth Rs m4,51626,832 16.8%   
Long term debt Rs m1,61825 6,472.8%   
Total assets Rs m8,29136,900 22.5%  
Interest coverage x1.11,305.5 0.1%   
Debt to equity ratio x0.40 38,458.4%  
Sales to assets ratio x0.50.5 90.4%   
Return on assets %5.19.8 52.2%  
Return on equity %1.813.4 13.1%  
Return on capital %6.320.4 30.8%  
Exports to sales %00-   
Imports to sales %18.40-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m736NA-   
Fx inflow Rs m022 0.0%   
Fx outflow Rs m7361,489 49.5%   
Net fx Rs m-736-1,466 50.2%   
CASH FLOW
From Operations Rs m9973,318 30.1%  
From Investments Rs m-461-2,383 19.4%  
From Financial Activity Rs m-571-1,104 51.7%  
Net Cashflow Rs m-35-169 20.8%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 0.2 7.5 2.4%  
FIIs % 0.6 4.9 11.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 23.7 280.2%  
Shareholders   20,121 85,207 23.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Nifty Crosses 11,500-Mark; L&T Surges 4% on Buyback News(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.2% while the Hang Seng is up 0.7%.

Related Views on News

PFIZER Announces Quarterly Results (1QFY19); Net Profit Up 60.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, PFIZER has posted a net profit of Rs 918 m (up 60.6% YoY). Sales on the other hand came in at Rs 5 bn (up 18.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (4QFY18); Net Profit Up 53.6% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, PFIZER has posted a net profit of Rs 1 bn (up 53.6% YoY). Sales on the other hand came in at Rs 5 bn (up 14.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Aug 20, 2018 10:45 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS